Pharmacodynamic Properties and Clinical Trial of Idarubicin Hydrochloride

Idarubicin Hydrochloride is an anthracycline cell cycle-nonspecific anticancer drug. It is primarily used for the treatment of malignant tumors such as acute non-lymphocytic leukemia and acute lymphocytic leukemia (as a second-line treatment), as well as advanced breast cancer. It is also applied in myelodysplastic syndromes and non-Hodgkin's lymphoma. The mechanism of action of Idarubicin Hydrochloride includes inhibition of DNA synthesis, interference with RNA polymerase and topoisomerase II activity, and its potency is eight times that of daunorubicin.

Figure1: Picture of Idarubicin Hydrochloride

Basic Introduction

Idarubicin Hydrochloride is a 4-demethoxy-anthracycline analogue of daunorubicin which, when administered intravenously in combination with cytarabine, has the rapeutic efficacy superior to that of standard induction and salvage treatment regimens in acute myelogenous leukaemia. Idarubicin Hydrochloride alone or in combination regimens has also been effective in limited studies in patients with other acute leukaemias, advanced breast cancer, multiple myeloma and non-Hodgkin's lymphoma. Idarubicin is more lipophilic than its parent drug daunorubicin. Idarubicin Hydrochloride intercalates DNA, induces DNA strand breaks and delays cell cycle progression. Leucopenia is often dose-limiting in patients with solid tumours treated with idarubicin, and most other adverse effects are similar in incidence and severity to those experienced with other anthracycline cytotoxic agents, except for alopecia which appears to occur with a reduced incidence and severity. Cardiotoxic effects have been reported with idarubicin as with other anthracyclines, but animal data and preliminary clinical findings suggest the possibility of reduced cardiotoxicity with idarubicin — a potentially important advantage if confirmed on further study. A maximum cumulative dose of idarubicin beyond which the incidence of cardiotoxicity rapidly increases has not been determined. [1]

Pharmacodynamic Properties

Due to the absence of a methoxyl group at position 4 of its anthracycline structure, Idarubicin Hydrochloride exhibits increased lipophilicity and a faster rate of cellular uptake compared to daunorubicin. Idarubicin Hydrochloride is 10-fold more cytotoxic than daunorubicin, demonstrating greater activity than either daunorubicin or doxorubicin against cultured human cancer cells. The primary metabolite, idarubicinol, shows similar in vitro activity to Idarubicin Hydrochloride. Both Idarubicin Hydrochloride and its metabolite demonstrate superior antitumor activity to doxorubicin, and at least equivalent activity to daunorubicin, in experimental leukemia models in vivo following either intravenous or oral administration. Importantly, the ratio of cardiotoxic to antitumor dose for Idarubicin Hydrochloride exceeds that for daunorubicin and doxorubicin. Idarubicin Hydrochloride intercalates DNA, disrupting nucleic acid synthesis. It induces DNA strand breaks by inhibiting DNA topoisomerase II and generating free radicals, arresting cells in the G2 phase of the cell cycle. Animal toxicity tests demonstrate that Idarubicin Hydrochloride has decreased cardiotoxicity compared with daunorubicin and doxorubicin; hematolymphopoietic and gastrointestinal symptoms were consistent with those observed with other cytotoxic agents. [1]

Clinical Trial

Based on its in vitro activity in leukemic cell lines and the results of Phase I studies in acute leukemia, Phase II and III clinical trials with Idarubicin Hydrochloride were subsequently conducted in patients with acute lymphocytic leukemia or acute nonlymphocytic leukemia. In the Phase III comparative trials evaluating combinations of Idarubicin Hydrochloride with cytarabine versus daunorubicin hydrochloride with cytarabine, the regimen containing Idarubicin Hydrochloride resulted in significantly higher complete remission rates and longer overall survival in two of the three studies conducted in the United States. Consequently, in September 1990, the U.S. Food and Drug Administration granted approval for the intravenous use of Idarubicin Hydrochloride with a Class 1A rating, specifically for administration in combination with other antileukemic agents (e.g., cytarabine) for the treatment of acute myelogenous leukemia in adults. When used in combination with cytarabine, the recommended dose of Idarubicin Hydrochloride is 12 mg/m² administered daily by slow intravenous injection for three consecutive days. Although Idarubicin Hydrochloride causes myelosuppression similar to that observed with daunorubicin, the incidence of cardiotoxicity in animal models is lower. Idarubicin Hydrochloride also offers the potential advantage of oral administration; however, its oral formulation remains investigational. Furthermore, the use of Idarubicin Hydrochloride in pediatric patients has yet to be established. [2]

Reference

[1] Hollingshead L M, Faulds D. Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer[J]. Drugs, 1991, 42(4): 690-719.

[2] Fields S M, Koeller J M. Idarubicin: a second-generation anthracycline[J]. Dicp, 1991, 25(5): 505-517.

You may like